

Supplemental Appendix

Supplement to: Adherence and persistence to nusinersen for spinal muscular atrophy: a US claims-based analysis

David Fox,¹ Tu My To,¹ Arpamas Seetasith,¹ Anisha M. Patel,¹ Susan T. Iannaccone²

¹Genentech Inc, South San Francisco, CA, USA


²Departments of Pediatrics and Neurology, Division of Pediatric Neurology, University of Texas Southwestern Medical Center and Children's Medical Center Dallas, USA

Corresponding author:


David Fox

Email: fox.david@gene.com

Supplemental Figure 1. Algorithm to identify nusinersen claims.




Supplemental Figure 2. Expected time periods for nusinersen dosing schedule with and without grace periods included.



Supplemental Figure 3. Persistence analysis for base case.


1. Discontinuation = **2 missed doses** based on the expected dosing schedule



2. Discontinuation date = expected date of the first missed dose

3. Grace periods of 7 days for loading doses and 28 days for maintenance doses

Supplemental Figure 4. Kaplan-Meier plot of persistence over time in sensitivity analysis. *Discontinuation definition: 1 missed dose and grace period (7 days for loading doses, 60 days for maintenance doses).



Supplemental Table 1. Coding criteria.

Criterion	<i>International Classification of Diseases, Tenth Revision Code (unless otherwise specified)</i>
Pregnancy	Z34.x; V220; V221
SMA diagnosis codes	G12.0x, G12.1x, G12.8x, G12.9x
Nusinersen treatment	Healthcare Common Procedure Coding System code C9498; J-code J232; National Drug Code 6440610-058-01
Lordosis	737.2x, M40.4x, M40.5x, 737.42
Spondylolisthesis	737.40, M43.0x, M43.1x, 756.12, 'Q76.2
Kyphosis	737.0, M40.0x, M40.1x, M40.2x, 737.1x, 737.41
Scoliosis	737.3x, M41.x, 737.40, 737.43, 737.8x, 737.9x
Scoliosis correction surgery	22800, 22802, 22804, 22808, 22810, 22812, 22814, 22816, 22818, 22819, 22842, 22843, 22844, 22845, 22846, 22847, 22848, 22849, 22899